healthcare

healthcare Articles

BioMarin Pharmaceutical stock was crushed on Wednesday after an FDA response regarding its valoctocogene roxaparvovec gene therapy for severe hemophilia A.
Vanda Pharmaceuticals took another big step forward in the fight against COVID-19 on Tuesday morning.
XBiotech shares made a handy gain on Monday after the company said that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2.
Unity Biotechnology stock was absolutely crushed on Monday after the company announced results from its midstage study in patients with moderate-to-severe painful osteoarthritis of the knee.
Principia Biopharma shares jumped to start out the week after it was announced that it would be acquired by Sanofi.
CureVac stock exploded into the market, more than double its original pricing. Since then, it is up more or less triple its original pricing.
Taiwan Liposome Co. Ltd (NASDAQ: TLC) shares shot higher on Friday after the company announced it was making a regulatory filing for a COVID-19 treatment that has been at the center of some...
When Moderna announced a new deal with the U.S. government for its COVID-19 vaccine, it appeared be a case of “sell the news,” because this is ultimately a net positive for the company.
Royalty Pharma reported quarterly results on Wednesday morning that were boosted by Imbruvica and the addition of new royalties.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Tilray reported disappointing quarterly results after the market closed on Monday, and many analysts took to the sidelines.
Eyenovia shares soared on Tuesday after the company announced an exclusive license agreement with Artic Vision.
24/7 Wall St. has compiled a list of some speculative biotech plays that could see gains of up to 300% in the coming months.
Seres Therapeutics shares more than tripled early on Monday after the firm announced positive late-stage results for its C. difficile infection study.
AnPac Bio-Medical Science shares surged higher on Friday after the company reaffirmed its status as a COVID-19 stock.